Beyond Air (Beyond Air) Change In Working Capital : $-7.06 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Beyond Air Change In Working Capital?

Beyond Air's change in working capital for the quarter that ended in Dec. 2023 was $-3.76 Mil.

Beyond Air's change in working capital for the fiscal year that ended in Mar. 2023 was $5.39 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Beyond Air Change In Working Capital Historical Data

The historical data trend for Beyond Air's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beyond Air Change In Working Capital Chart

Beyond Air Annual Data

Trend

Jun15

Jun16

Dec17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Change In Working Capital

Get a 7-Day Free Trial

2.13

-1.13

-1.20

11.83

5.39

Beyond Air Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															-0.64	8.14	-7.80	-3.64	-3.76

Beyond Air Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.06 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Beyond Air Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Beyond Air's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Beyond Air (Beyond Air) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Beyond Air Inc (NAS:XAIR) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

48L:Germany

Address

900 Stewart Avenue, Suite 301, Garden City, New York, NY, USA, 11530

Website

https://www.beyondair.net

Beyond Air Inc is a clinical-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Executives

Amir Avniel	director, officer: President & CEO	2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Jeff Lynn Myers	officer: Chief Medical Officer	C/O BEYOND AIR, INC., 900 STEWART AVENUE, SUITE 301, GARDEN CITY NY 11530
Robert Carey	director	HORIZON PHARMA, INC., 520 LAKE COOK ROAD, SUITE 520, DEERFIELD IL 60062
Steven A. Lisi	director	2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Michael A. Gaul	officer: Chief Operating Officer	425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213
William P Forbes	director	C/O SALIX PHARMACEUTICALS, LTD., 8510 COLONNADE CENTER DRIVE, RALEIGH NC 27615
Yoori Lee	director	C/O AIT THERAPEUTICS, INC., 500 MAMARONECK AVENUE, HARRISON NY 10528
Ron Bentsur	director	750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Erick Lucera	director	138 THISTLE ROAD, NORTH ANDOVER MA 08145
Douglas Quinton Larson	officer: Chief Financial Officer	BEYOND AIR, INC., 900 STEWART AVENUE, SUITE 301, GARDEN CITY NY 11530
Douglas Beck	officer: Chief Financial Officer	C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Ari Raved	director	2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Jerome B Zeldis	director	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
David Grossman	director	2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Haim Aviv	officer: Chief Financial Officer	2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635